Carnitine insufficiency is associated with fatigue during lenvatinib treatment in patients with hepatocellular carcinoma-Reference-Cited by-同舟云学术

Carnitine insufficiency is associated with fatigue during lenvatinib treatment in patients with hepatocellular carcinoma

Published:2020-03-03 Issue:3 Volume:15 Page:e0229772
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Okubo Hironao^ORCID,Ando Hitoshi^ORCID,Ishizuka Kei,Kitagawa Ryuta,Okubo Shoki,Saito Hiroaki,Kokubu Shigehiro,Miyazaki Akihisa,Ikejima Kenichi,Shiina Shuichiro,Nagahara Akihito

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference29 articles.

1. The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting;S Obi;Hepatol Int,2019

2. Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis;A Hiraoka;Cancer Med,2019

3. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial;M Kudo;Lancet,2018

4. A review of the logistic role of L-carnitine in the management of radiation toxicity and radiotherapy side effects;HA Khan;J Appl Toxicol,2011

5. Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin;MJ Hockenberry;J Pediatr Hematol Oncol,2009

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study;Clinical Cancer Research;2024-04-05

2. Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma;Targeted Oncology;2024-01

3. Serum Metabolite Biomarkers for Pancreatic Tumors: Neuroendocrine and Pancreatic Ductal Adenocarcinomas—A Preliminary Study;Cancers;2023-06-19

4. The association of serum carnitine levels with severity of fatigue in patients with multiple sclerosis: A pilot study;Current Journal of Neurology;2023-05-03

5. L-carnitine prevents lenvatinib-induced muscle toxicity without impairment of the anti-angiogenic efficacy;Frontiers in Pharmacology;2023-04-06